US FDA orders new eye risk warnings for Ozempic, Zepbound

The regulator requires Lilly and Novo Nordisk to add warnings about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, painless vision loss and, in some cases, permanent sight impairment.